Future Mingyi Medical Files IPO: Redefining AI Home Doctor Deployment Through Cardiovascular Health Wearables

As an “intelligent decision-making participant” throughout the entire course of chronic disease management, the implementation format of AI doctors in consumer-facing scenarios will directly impact patient adherence. Questions such as “What is the optimal product form for deploying AI family doctors?” and “How can AI doctors maintain high-frequency online availability?” are increasingly becoming key topics of industry focus.

“Currently, AI family doctors mostly interact with patients through mobile apps. However, in reality, we only use a handful of apps regularly. Aside from daily social and entertainment software, most apps may not be opened more than a few times a year.”Xu Bo, Founder and CEO of Future Mingyi Technology (Shenzhen) Co., Ltd. (hereinafter referred to as “Future Mingyi”)He shared that healthcare management scenarios are inherently low-frequency, while user retention in the mobile app ecosystem is generally constrained by “high-frequency usage inertia.” This makes it difficult to sustain the monthly active users (MAU) of apps featuring AI doctors, rendering them prone to being forgotten.

"Therefore,"I believe the optimal implementation scenario for AI doctors is not mobile apps..” Mr. Xu stated that the service scenarios of AI family doctors need to be deeply integrated into users’ daily lives, whereas a lightweight form relying solely on mobile apps struggles to meet core requirements such as proactive user engagement and real-time data collection, thereby failing to resolve the contradiction between low-frequency usage and high-frequency health management needs. From this perspective,He believes that home-use medical devices represent the ideal form of implementation for AI doctors.

Among these, smart blood pressure monitors, as the most widely adopted health monitoring devices in households, boast broad user coverage and high frequency of use. Some users even develop a habit of daily measurement, creating a stable “device usage traffic” that provides a natural scenario for AI-driven interactions.

Consequently, Mingyi has developed a smart blood pressure monitor as the hardware terminal for its AI Doctor. This device integrates the AI Doctor, enabling users to communicate with it in real time during blood pressure measurements. This approach eliminates the “activation barrier” associated with apps that require proactive opening by users, thereby fostering habitual interaction with the AI Doctor through a natural usage workflow. Furthermore, the relatively larger form factor of the blood pressure monitor provides ample hardware space for integrating AI functional modules.

In addition, some users measure their blood pressure infrequently, resulting in correspondingly low interaction rates with the AI Doctor. To address this issue, Mingyi has developed a blood pressure and ECG smartwatch that integrates with the AI Doctor, ensuring high-frequency user engagement through prolonged wear. Once the watch is worn, the device can interact with users via vibration alerts and on-screen pop-ups. Users can also naturally engage with the AI Doctor during routine activities such as checking the time or receiving notifications, thereby enhancing the AI Doctor’s user reach efficiency and service stickiness.

The focus of future healthcare will gradually shift from “hospital-centric, treatment-oriented” to “home-centric, prevention-oriented.” In this process, AI doctors, with medical wearables and health-care robots as their hardware carriers, may play an indispensable role as a new form of productive forces. Among these, AI-enabled smart blood pressure monitors are likely to serve as transitional products for home-based AI doctors, owing to their high usage frequency, affordability, and high user awareness.

As the “number one killer” threatening global human health and longevity, cardiovascular disease presents a grim outlook, with two out of every five deaths in China attributed to it. Particularly as China’s population ages, the incidence of stroke and myocardial infarction continues to rise, making cardiovascular health management increasingly urgent.

As a core indicator of cardiovascular disease, blood pressure monitoring is an essential need. Consequently, blood pressure monitors account for the largest market segment among home medical devices for cardiovascular diseases. According to Xu Bo, Founder and CEO of Future Mingyi, the household penetration rate of blood pressure monitors in developed countries such as Germany and the United States is approximately 70%, whereas in China it stands at only 20%–30%, indicating substantial room for growth. Meanwhile, the global market size for blood pressure monitors is showing steady growth, with promising prospects.

Meanwhile, with the optimization and upgrading of core components such as sensors and air pumps, along with advancements in algorithms and artificial intelligence technologies, portability and intelligence have increasingly become the key directions for the evolution of blood pressure monitors.

Currently, leading domestic ICT suppliers have achieved significant breakthroughs in this field by developing blood pressure monitoring watches. However, their prices are dozens of times higher than those of traditional blood pressure monitors, rendering them unaffordable for the vast majority of users. This has spurred the emergence of some low-cost solutions, but these have failed to achieve widespread adoption due to substandard product performance. Consequently, a peculiar phenomenon has arisen in the industry: high-quality, high-priced blood pressure monitoring watches account for approximately 70% of the market share, while other low-priced products hold a minimal share due to performance deficiencies.

Against this backdrop, the market urgently needs blood pressure monitor watches that offer more stable performance and lower prices. This is one of the core reasons why Xu Bo founded Future Mingyi. Moreover, Future Mingyi’s ultimate goal does not stop here, but ratherLeveraging blood pressure and ECG smartwatches integrated with AI-powered physicians to deliver out-of-hospital cardiovascular health solutions.

Xu Bo, Founder and CEO of Future Mingyi, holds a background in clinical medicine and subsequently conducted postdoctoral research at the University of Nebraska Medical Center in the United States. Upon returning to China in 2013, Xu served as Medical Director at an internet healthcare company. At that time, when mobile health was in its nascent stage, the company launched China’s first CFDA-certified ECG patch product, integrating mobile health technologies for the management of chronic cardiovascular diseases. Later, he held positions as Head of the Product Department at Lifesense Medical and as Head of the Innovative Product Line and Digital Therapeutics Department at Future Wearables. With a decade of medical research experience focused on cardiovascular care, Xu also brings 11 years of expertise in the interdisciplinary field of medical wearable hardware and software, along with a track record of shipping tens of millions of units of health wearable products.

Regarding the current pain points in cardiovascular health management, Xu Bo pointed out that, in addition to the lack of “high-quality and affordable” blood pressure-monitoring smartwatches, there are also pain points related to patient adherence and business models. On one hand, due to low patient adherence, few models have achieved large-scale commercial implementation. Over time, mobile healthcare has gradually deviated from its original intent, remaining limited to basic connectivity functions—such as appointment registration and medication purchasing—without truly addressing the core area: comprehensive chronic disease management. On the other hand, while some solutions have not been highly successful commercially, they have achieved certain effects through intensive manual intervention. However, although such approaches can improve patient adherence, they suffer from low efficiency, high labor costs, and limited commercial value.

As generative AI achieves technological breakthroughs, AI physicians are becoming capable of replacing family doctors, effectively addressing the lack of synergy between the application of chronic disease management technologies and their commercial implementation. This development is ushering in new opportunities for cardiovascular chronic disease management. Amidst these technological trends and market dividends,Weilai Mingyi positions itself to focus on “empowering AI doctors with hardware terminals,” facilitating the deployment and application of AI doctors in the consumer market.Currently, the company’s developed blood pressure and ECG smartwatch can accurately monitor parameters such as blood pressure, heart rate, electrocardiogram (ECG), and blood oxygen saturation. The first-generation product has already received regulatory approval, and the second-generation product is expected to obtain FDA approval this year.

Traditional electronic blood pressure calculation chips suffer from low computational power, leading to limited measurement accuracy, increased risk of error, slow response times, and an inability to support intelligent upgrades. The algorithmic chips used by Future Mingyi have been upgraded, achieving storage capacity and computational power more than ten times that of traditional sphygmomanometers. Furthermore, Future Mingyi has developed a dual-algorithm system comprising “local” and “server-side” components using machine learning methods. This approach not only meets the immediacy requirements for medical-grade measurements but also enables “intelligent evolution” capabilities—such as model iteration, personalized adaptation, and long-term health management—through cloud-based big data and machine learning, features unattainable with traditional blood pressure monitors.

In addition, as a relatively novel product form, the most critical technical feature of blood pressure watches is the miniaturization of traditional sphygmomanometers. In this process, the air pump is the most crucial component. Currently, blood pressure watches from leading domestic ICT suppliers adopt imported air pump components, and their high procurement costs directly drive up the retail price of end products. Meanwhile, domestically produced air pumps often suffer from stability issues and patent risks. Therefore, overall,The supply chain for air pump components still has significant shortcomings, and true localization has not yet been achieved. “To truly bring blood pressure-monitoring smartwatches to the mass market, we must achieve in-house development of air pump modules,” said Xu Bo. He introduced that Mingyi’s self-developed air pump components will match the performance of foreign brands while reducing costs by 60%–70%., expected to receive FDA approval this year.

The performance stability of the air pump assembly is strongly correlated with the accuracy of blood pressure detection. From the perspective of technological R&D, its development is not merely a mechanical engineering issue but an interdisciplinary field that relies heavily on algorithmic technologies. Only by systematically synergizing algorithmic models with the design parameters of air pump hardware to establish a technical closed loop of “software-defined hardware and hardware-embedded algorithms” can core challenges—such as optimizing measurement precision, ensuring device stability, and enabling scalable mass production—be effectively addressed. In this regard, the interdisciplinary background of WeDoctor’s core team has laid a solid foundation for the R&D of air pump assemblies.

Regarding the selection of technical routes for air pump assemblies, two typical technological pathways exist within the industry. One approach employs piezoelectric ceramic film technology, which relies on the material properties of ceramic elements to achieve pneumatic drive; however, this method faces significant challenges due to substantial fluctuations in mass-production yield rates and high material costs. Weiyi Medical has adopted a diaphragm pump solution, featuring a miniaturized design of the mechanical pumps used in traditional electronic blood pressure monitors, thereby offering significant cost advantages. According to Xu Bo, the core reason this solution had not been effectively implemented in the industry previously was the lack of synergy between algorithm development and product R&D capabilities.Leveraging its robust algorithm R&D capabilities and comprehensive whole-system development experience, Weilai Mingyi has optimized the structure and fine-tuned the performance of diaphragm pumps based on their operating principles, achieving stable operation and readiness for large-scale mass production.

Specifically, the micro air pump components of Future Mingyi have the following technical characteristics:

● Proprietary custom development miniaturizes traditional mechanical diaphragm pumps, achieving the industry’s smallest air pump;

● Innovatively designed a specialized air chamber to buffer air pressure and stabilize airflow, ensuring the stability of pulse wave signals;

● Custom-developed micron-level deflation valve for precise airflow control;

● Breaks through the traditional amplitude coefficient method of sphygmomanometers and employs machine learning to enhance blood pressure measurement accuracy.

Cardiovascular diseases are characterized by their transient and sudden onset. First, 90% of cardiovascular events occur outside of hospital settings, meaning patients often miss the optimal window for diagnostic testing by the time they reach a medical facility. This leads to another significant issue: low patient awareness. Due to the lack of timely medical testing during onset, many patients struggle to accurately assess their condition, with some remaining entirely unaware that they have cardiovascular disease. Furthermore, the sudden nature of these events, coupled with high rates of mortality and disability, poses substantial health threats and psychological burdens to patients. These factors collectively underscore the critical importance of continuous monitoring of blood pressure and electrocardiogram (ECG) signals.

Taking hypertension as an example, human blood pressure exhibits dynamic fluctuations influenced by lifestyle, environmental factors, pathology, and medications. Its trends and characteristics hold significant value for clinical diagnosis. Currently, the hypertension control rate in China is only 20%–30%, compared to approximately 50% in the United States. This implies thatUp to half or more of hypertensive patients fail to achieve effective disease control even after receiving medical treatment. This is because current blood pressure monitoring methods typically rely on casual measurements, leading to imprecise determination of etiology and pathological classification.

The Blood Pressure and ECG Watch by Future Mingyi enables continuous blood pressure monitoring, helping patients measure their blood pressure anytime and anywhere and clearly understand trends in blood pressure changes.. Through functional iterations, its blood pressure and ECG smartwatch can achieve oscillometric blood pressure measurement, photoplethysmographic (PPG) blood pressure measurement, as well as monitoring of multiple parameters including electrocardiogram (ECG), blood oxygen saturation, atrial fibrillation risk, sleep, and heart rate variability. In addition, it alsoOffers a comprehensive suite of solutions to reduce the risk of stroke and myocardial infarction., incorporating 4G functionality to enable real-time risk alerts and provide intervention plans.

Taking stroke as an example, the two key factors leading to stroke are hypertension and atrial fibrillation. The next-generation blood pressure and ECG smartwatch from Future Mingyi will integrate digital therapeutics to monitor multidimensional health information, including patients’ blood pressure, blood oxygen levels, physical activity, sleep status, and mental stress. It will perform correlation analysis with the patient’s hypertension condition and provide precise intervention plans.

Furthermore, low patient adherence is a key factor contributing to the low control rates of cardiovascular diseases. In the future, Mingyi will effectively address this challenge by integrating AI-powered physicians into blood pressure and ECG smartwatches.

First, from the perspective of user acquisition, traditional mobile-based AI doctors rely on app promotion, which entails high customer conversion costs and requires screening for alignment between user needs and product features. In contrast, users of blood pressure and ECG smartwatches represent a naturally precise target audience; those who purchase such devices typically already have clear cardiovascular health management needs. This approach significantly reduces customer acquisition costs while directly reaching individuals who genuinely require AI-powered medical services.

In terms of user engagement, the daily habit of wearing a smartwatch naturally ensures a 100% daily active user (DAU) rate for the device, a benchmark that mobile apps struggle to achieve due to varying user habits. Furthermore,Data acquisition capability is one of the core competencies of the AI doctor on smartwatches.. Mobile apps lack native hardware support, and their health data collection heavily relies on manual user input or cross-device synchronization, limiting both data completeness and real-time availability. WhereasBlood pressure and ECG smartwatches can automatically collect multi-dimensional health data, construct dynamic and comprehensive user health profiles, and enable precise interventions based on individual characteristics.。

Unlike traditional blood pressure monitors, which are limited to measuring only blood pressure, Mingyi’s future blood pressure watch will serve as a hub for multi-dimensional health data collection and user interaction, becoming an AI-powered cardiovascular doctor on your wrist.

In terms of business model, Future Mingyi has developed two models: the Hi Model and the Mingyi Zhikang Model. The former targets customers with manufacturing capabilities, providing technical support such as air pump components and algorithm empowerment, enabling these customers to manufacture and sell the complete devices. The latter is designed for digital health enterprises, with Future Mingyi deeply engaging in product design, software-hardware collaboration, and full-device development.

In terms of market layout, Mingyi will primarily focus on Europe and the United States in overseas markets, adopting an OEM private-label sales model, and has already reached collaborations with several leading home medical device companies; domestically, it has completed shipments of thousands of units, with sales channels mainly consisting of large-client OEM models and offline gift and health-care channel sales.

Going forward, Future Mingyi will continue to deepen its expertise in the health management of chronic cardiovascular diseases, striving to become the “Garmin of the healthcare industry” and a leading enterprise in medical wearable products.